Cargando…

Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood

BACKGROUND: There are limited methods to predict the therapeutic effect of immune checkpoint inhibitors (ICIs). The purpose of this study was to explore the value of circulating microparticles (MPs) in predicting thetherapeutic effects of immunotherapy. METHODS: A prospective study was conducted at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Tingting, Wang, Jiang, Liu, Yanxin, Wu, Jionghe, Yuan, Yaping, Wang, Chao, Fang, Xiangqun, Li, Hongxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903816/ https://www.ncbi.nlm.nih.gov/pubmed/33612078 http://dx.doi.org/10.1177/1533033821997817

Ejemplares similares

Early warning of bloodstream infection in elderly patients with circulating microparticles
por: Liu, Tingting, et al.
Publicado: (2021)

Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles
por: Liu, Tingting, et al.
Publicado: (2021)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Incidence and Associated Risk Factors for Lactic Acidosis Induced by Linezolid Therapy in a Case–Control Study in Patients Older Than 85 Years
por: Liu, Tingting, et al.
Publicado: (2021)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
por: Cui, Pengfei, et al.
Publicado: (2020)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier
por: Abid, Haisam, et al.
Publicado: (2019)

Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients
por: Wang, Chin-Chou, et al.
Publicado: (2017)

Circulating Endothelial Progenitor Cell and Platelet Microparticle Impact on Platelet Activation in Hypertension Associated with Hypercholesterolemia
por: Alexandru, Nicoleta, et al.
Publicado: (2013)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Increased circulating platelet and endothelial-derived microparticles in patients with cardiac syndrome X
por: Ghaffari, Fereshteh, et al.
Publicado: (2021)

Platelet-Derived Microparticles and Autoimmune Diseases
por: Li, Xiaoshuai, et al.
Publicado: (2023)

Circulating Endothelial Cells and Microparticles as Prognostic Markers in Advanced Non-Small Cell Lung Cancer
por: Fleitas, Tania, et al.
Publicado: (2012)

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Lipid profile of platelets and platelet-derived microparticles in ovarian cancer
por: Hu, Qianghua, et al.
Publicado: (2016)

Circulating microparticles and activated platelets as novel prognostic biomarkers in COVID-19; relation to cancer
por: Zahran, Asmaa M., et al.
Publicado: (2021)

Small-Size Circulating Endothelial Microparticles in Coronary Artery Disease
por: Hu, Shuai-Shuai, et al.
Publicado: (2014)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Polyphenols: Modulators of Platelet Function and Platelet Microparticle Generation?
por: Ed Nignpense, Borkwei, et al.
Publicado: (2019)

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
por: Lin, Shu-Yung, et al.
Publicado: (2018)

Increased levels of circulating platelet-derived microparticles in psoriasis: Possible implications for the associated cardiovascular risk
por: Papadavid, Evangelia, et al.
Publicado: (2016)

Circulating microparticles: square the circle
por: Barteneva, Natasha S, et al.
Publicado: (2013)

Platelet Microparticle Controversial Role in Cancer
por: Nazari, Mahnaz, et al.
Publicado: (2021)

Correction: Small-Size Circulating Endothelial Microparticles in Coronary Artery Disease
Publicado: (2014)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center
por: Hall, Evan, et al.
Publicado: (2020)

RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
por: Siddiqui, Jalal, et al.
Publicado: (2021)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

Circulating Microparticles and Coagulation Profiles in Patients with Advanced Stage Solid Tumors
por: Sun, Der Sheng, et al.
Publicado: (2018)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Ogiwara, Toshiki, et al.
Publicado: (2021)

Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity
por: Chiva-Blanch, Gemma, et al.
Publicado: (2017)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing
por: Wang, Buhai, et al.
Publicado: (2022)

Real-World Outcomes of Nivolumab, Pembrolizumab, and Atezolizumab Treatment Efficacy in Korean Veterans with Stage IV Non-Small-Cell Lung Cancer
por: Ham, Ahrong, et al.
Publicado: (2023)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_535l94m25glufsmn9fciprrg46